Phase 1 and dose expansion study of APR-246 in combination with ibrutinib or venetoclax-based therapy in subjects with TP53-mutant relapsed and/or refractory non-hodgkin lymphomas (NHL) including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) Meeting Abstract

  

Authors:	Thompson, M. C.; Davids, M. S.; Jain, N.; Soumerai, J. D.; Geethakumari, P. R.; Gubits, A.; Hickman, D.; Wennborg, A.; Attar, E. C.; Abdel-Wahab, O.; Mato, A. R.
Abstract Title:	Phase 1 and dose expansion study of APR-246 in combination with ibrutinib or venetoclax-based therapy in subjects with TP53-mutant relapsed and/or refractory non-hodgkin lymphomas (NHL) including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)
Meeting Title:	62nd Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	136
Issue:	Suppl. 1
Meeting Dates:	2020 Dec 5-8
Meeting Location:	Virtual
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2020-11-05
Language:	English
ACCESSION:	WOS:000607547201134
DOI:	10.1182/blood-2020-139022
PROVIDER:	wos
Notes:	Meeting Abstract: 15 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/197891